Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6417
    -0.0009 (-0.14%)
     

  • OIL

    83.13
    +0.40 (+0.48%)
     

  • GOLD

    2,409.90
    +11.90 (+0.50%)
     

  • Bitcoin AUD

    100,160.69
    +1,824.06 (+1.85%)
     

  • CMC Crypto 200

    1,383.37
    +70.75 (+5.60%)
     

  • AUD/EUR

    0.6022
    -0.0008 (-0.14%)
     

  • AUD/NZD

    1.0898
    +0.0023 (+0.21%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,015.91
    -378.40 (-2.18%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,898.13
    +122.75 (+0.32%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Immunovant to Participate in Roivant R&D Day 2021

Immunovant
·1-min read

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET.

A live webcast of the event can be accessed at www.tinyurl.com/roivant. A replay of the event will be archived under the ‘Events’ section on the Investors page at www.immunovant.com for 30 days following the presentation.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com